Immunogen (IMGN) Misses Q2 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. SPY
6. META
7. BA
8. HOOD
9. INTC
10. JBLU

Go back to Immunogen (IMGN) Misses Q2 EPS by 2c

ImmunoGen Reports Second Quarter Fiscal Year 2016 Financial Results and Provides Corporate Update

January 29, 2016 6:30 AM EST

Conference Call Today at 8:00 am ET

Both ImmunoGens FORWARD I and FORWARD II clinical trials are open for patient enrollment. FORWARD I is designed to support an Accelerated Approval pathway for lead program mirvetuximab soravtansine and FORWARD II assesses this first-in-class folate receptor (FR)-targeting antibody-drug conjugate (ADC) in multiple combination regimens. Bayer has initiated a Phase 2 study designed to support registration of anetumab ravtansine, its mesothelin-targeting ADC. Anetumab ravtansine is the second partner ADC after Roches Kadcyla® with ImmunoGen technology to advance into potential registration testing. Roche expects... More